[{"orgOrder":0,"company":"Cyclica","sponsor":"Cyclica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroTheryX Partners with Cyclica to Launch NineteenGale Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"N\/A","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"N\/A"},{"orgOrder":0,"company":"Cyclica","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerevel Therapeutics and Cyclica Collaborate to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in Neuroscience","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Cyclica","sponsor":"Structural Genomics Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclica and the Structural Genomics Consortium Co-crystallize DCAF1, a Key Component in Proteasomal Degradation, With a Novel Ligand to Support Targeted Therapeutics Discovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclica and Arctoris to Expand Partnership to Advance Drug Discovery Programs for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Cyclica","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"}]
Find Clinical Drug Pipeline Developments & Deals by Cyclica
Through the acquisition, Cyclica's two highly differentiated products in the digital chemistry space which will be integrated into the Recursion OS, including MatchMaker™, an AI-enabled deep learning engine that predicts the polypharmacology of small molecules and POEM™.
Cyclica’s platform and capabilities in combination with the biological assay development of Arctoris will enable us to yield meaningful results and advance research development for patients suffering from Alzheimers and other neurodegenerative diseases.
As part of the initiative, the SGC and Cyclica examined three WDR proteins to discover small molecule binders using Cyclica’s proprietary deep learning platform to assess commercially available libraries for potential binders.
Cerevel will utilize Cyclica’s Ligand Express® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines.
Under the initial stealth project, NeuroTheryX combined their phenotype-based drug discovery platform with Cyclica’s first-in-class proteome screening platform.